Full Press Release Details
BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership With Catalent For Dedicated Gene Therapy Development And Manufacturing Capacity.
BBIO
BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership With Catalent For Dedicated Gene Therapy Development And Manufacturing Capacity
Key Takeaway: BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership With Catalent For Dedicated Gene Therapy Development And Manufacturing Capacity
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis